Applications | GMP Transfection for AAV Production
TransIT-VirusGEN® GMP Transfection Reagents and Kits
Nucleic Acid Delivery
- Achieve higher titers and percent full AAV capsids
- >50% savings on a cost per dose basis vs. the leading competitor
- Universally platformable across all AAV serotypes
ISO 13485:2016 Certified
Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio
View the certificateThe Highest Quality Grade for Cell & Gene Therapy
VirusGEN® is a proven transfection reagent combining industry-leading yield performance with real world economic
advantages by delivering a reduced cost per dose — all supported by comprehensive expertise for cell and gene therapy.
VirusGEN® specifications support virus production fit-for-purpose requirements.
Designed to be Biomimetic for Optimized Performance
What makes VirusGEN® unique?
- Mirus proprietary lipid and polymer technology
- Forms lipopolyplex with DNA (or nucleic acid)
- Biomimetic behavior increases transfection efficiency
What benefit does this bring?
- Higher titers vs. PEI (2-10x) and higher percent full AAV capsids
VirusGEN Outperforms Competitor Reagents in Various AAV Serotypes 
VirusGEN Percent Full Titer Consistently Outperforms Competitors
Documentation
Specifications
Storage Conditions:
VirusGEN® GMP AAV Transfection Kit: Multiple storage conditions – see individual bottles for specific recommendations
TransIT-VirusGEN® GMP Transfection Reagent: Store at -10 to -30°C
Product Guarantee:
All Configurations: Refer to Certificate of Analysis for Retest Date
Usage Statement:
All Configurations: For Research Use and Further Manufacturing; Not for Administration into Humans.
Animal Origin Statement:
All Configurations: This product is animal origin free.
Technical Product Literature
Directly From Our Customers
Listen to the first-hand account of how Mirus helped researchers from St. Jude overcome the challenges with viral vector optimization to produce ground-breaking gene therapy for hemophilia. Go to the podcast >>